natgillin/translations-raw huggingface dataset:
2000 IU per vial; after reconstitution with 5 ml of water for injections the solution contains 400 IU/ml of albutrepenonacog alfa. 
2000 i.e. na vialo; po pripravi s 5 ml vode za injekcije raztopina vsebuje približno 400 i.e./ml albutrepenonakoga alfa.
IDELVION 1000 IU powder and solvent for solution for injection 
IDELVION 1000 i.e. prašek in vehikel za raztopino za injiciranje
IDELVION 500 IU powder and solvent for solution for injection 
IDELVION 500 i.e. prašek in vehikel za raztopino za injiciranje
IDELVION 1000 IU powder and solvent for solution for injection 1 vial with powder 
IDELVION 1000 i.e. prašek in vehikel za raztopino za injiciranje 1 viala s praškom
500 IU per vial; after reconstitution with 2.5 ml of water for injections the solution contains 200 IU/ml of albutrepenonacog alfa. 
500 i.e. na vialo; po pripravi z 2,5 ml vode za injekcije raztopina vsebuje približno 200 i.e./ml albutrepenonakoga alfa.
IDELVION 2000 IU powder and solvent for solution for injection Albutrepenonacog alfa 
IDELVION 2000 i.e. prašek in vehikel za raztopino za injiciranje albutrepenonakog alfa
After reconstitution with 5 ml water for injections the solution contains 400 IU/ml of albutrepenonacog alfa. 
Po rekonstituciji s 5 ml vode za injekcije raztopina vsebuje 400 i.e./ml albutrepenonakoga alfa.
IDELVION 500 IU powder and solvent for solution for injection Albutrepenonacog alfa 
IDELVION 500 i.e. prašek in vehikel za raztopino za injiciranje albutrepenonakog alfa
250 IU per vial; after reconstitution with 2.5 ml of water for injections the solution contains 100 IU/ml of albutrepenonacog alfa. 
250 i.e na vialo; po pripravi z 2,5 ml vode za injekcije raztopina vsebuje približno 100 i.e./ml albutrepenonakoga alfa.
1000 IU per vial; after reconstitution with 2.5 ml of water for injections the solution contains 400 IU/ml of albutrepenonacog alfa. 
1000 i.e na vialo; po pripravi z 2,5 ml vode za injekcije raztopina vsebuje približno 400 i.e./ml albutrepenonakoga alfa.
IDELVION 250 IU powder and solvent for solution for injection Albutrepenonacog alfa 
IDELVION 250 i.e. prašek in vehikel za raztopino za injiciranje albutrepenonakog alfa
After reconstitution with 2.5 ml water for injections the solution contains 200 IU/ml of albutrepenonacog alfa. 
Po rekonstituciji z 2,5 ml vode za injekcije raztopina vsebuje 200 i.e./ml albutrepenonakoga alfa.
IDELVION 250 IU powder and solvent for solution for injection: 1 vial with powder 
IDELVION 250 i.e. prašek in vehikel za raztopino za injiciranje 1 viala s praškom
After reconstitution with 2.5 ml water for injections the solution contains 100 IU/ml of albutrepenonacog alfa. 
Po rekonstituciji z 2,5 ml vode za injekcije raztopina vsebuje 100 i.e./ml albutrepenonakoga alfa.
IDELVION 1000 IU powder and solvent for solution for injection Albutrepenonacog alfa 
IDELVION 1000 i.e. prašek in vehikel za raztopino za injiciranje albutrepenonakog alfa
Formation of inhibitor to factor IX has been reported during factor replacement therapy with IDELVION in the treatment of haemophilia B. After repeated treatment with human coagulation factor IX products, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing. 
Po nadomestnem zdravljenju z zdravilom IDELVION pri zdravljenju hemofilije B so poročali o nastanku inhibitorjev proti faktorju IX.
IDELVION 250 IU powder for solution for injection Albutrepenonacog alfa 
IDELVION 250 i.e. prašek za raztopino za injiciranje albutrepenonakog alfa za intravensko uporabo
After reconstitution with 2.5 ml water for injections the solution contains 400 IU/ml of albutrepenonacog alfa. 
Po rekonstituciji z 2,5 ml vode za injekcije raztopina vsebuje 400 i.e./ml albutrepenonakoga alfa.
IDELVION 2000 IU powder for solution for injection Albutrepenonacog alfa 
IDELVION 2000 i.e. prašek za raztopino za injiciranje albutrepenonakog alfa za intravensko uporabo
1 disposable 5 ml syringe 1 venipuncture set 
1 injekcijska brizga (5 ml) za enkratno uporabo 1 komplet za punkcijo vene
IDELVION 500 IU powder for solution for injection Albutrepenonacog alfa 
IDELVION 500 i.e. prašek za raztopino za injiciranje albutrepenonakog alfa za intravensko uporabo
IDELVION 1000 IU powder for solution for injection Albutrepenonacog alfa 
IDELVION 1000 i.e. prašek za raztopino za injiciranje albutrepenonakog alfa za intravensko uporabo
Attach the syringe to the threaded, locking end of the venipuncture kit. 
Pritrdite injekcijsko brizgo na navojni, zaporni del kompleta za punkcijo vene.
1 disposable 10 ml syringe 
1 viala s 5 ml vode za injekcije
Headache 
Krvavitev
Pharmaceutical Form Route of administrationPackaging 
Farmacevtska oblika Pot uporabe
This may be painful and can occur at any time. 
Lahko so boleče in se pojavijo kadar koli.
Frequency: common 
Pogostnost: pogosti
2 - What you need to know before you take <product name> Warnings and precautions 
2 - Kaj morate vedeti, preden boste vzeli zdravilo <ime zdravila> Opozorila in previdnostni ukrepi
Priapism. 
Priapizem.
It is important to contact your doctor straight away if your erection lasts for longer than 2 hours, particularly if this is painful. 
Pomembno je, da se takoj posvetujete z zdravnikom, če erekcija traja dlje kot 2 uri, zlasti če je boleča.
Benign polyps in the stomach 
Benigni polipi v želodcu
Adopted at the 28 November-1 December 2016 PRAC 
Sprejeto na seji odbora PRAC med 28. novembrom in 1. decembrom 2016
Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention. 
Bolniki, pri katerih se pojavijo nenormalno dolge ali pogoste in boleče erekcije, morajo takoj poiskati zdravniško pomoč.
During treatment, boys and adolescents may unexpectedly experience prolonged erections. 
Med zdravljenjem se pri dečkih in mladostnikih lahko nepričakovano pojavijo dolgotrajne erekcije.
In case calciphylaxis is diagnosed, appropriate treatment should be started and consideration should be given to stopping treatment with <product name>. 
Če se ugotovi kalcifilaksija, je treba začeti s primernim zdravljenjem in razmisliti o prekinitvi zdravljenja z zdravilom <ime zdravila>.
This adverse reaction occurs more frequently in patients with chronic kidney disease. 
Ti neželeni učinki se pogosteje pojavijo pri bolnikih s kronično ledvično boleznijo.
Summary of product characteristics (both prescription and non-prescription) 4.8. 
Povzetek glavnih značilnosti zdravila (na recept in brez recepta) 4.8.
4 - Possible side effects 
4 - Možni neželeni učinki
On rare occasions <product name> can cause serious skin conditions, including one called calciphylaxis that can start with a painful skin rash but can lead to serious complications. 
V redkih primerih lahko zdravilo <ime zdravila> povzroči resna kožna obolenja, vključno s kalcifilaksijo, ki se lahko začne z bolečim kožnim izpuščajem, a lahko vodi do pojava resnih zapletov.
Prolonged erections, sometimes painful, or an increased number of erections Frequency: not known 
Dolgotrajne erekcije, včasih boleče, ali večje število erekcij Neznana pogostnost
Summary of product characteristics (fluindione, phenindione) 
Povzetek glavnih značilnosti zdravila (fluindion, fenindion)
Package leaflet (both prescription and non-prescription) 4 - Possible side effects 
Navodilo za uporabo (na recept in brez recepta) 4 - Možni neželeni učinki
Undesirable effects Skin and subcutaneous tissue disorders Frequency ‘not known': Calciphylaxis 
Neželeni učinki Bolezni kože in podkožja Neznana pogostnost: kalcifilaksija
Vildagliptin; Vildagliptin, metformin - Pemphigoid (EPITT no 18692) 
Vildagliptin; vildagliptin, metformin - pemfigoid (št. EPITT 18692)
Gastrointestinal disorders: Fundic gland polyps (benign) Frequency: common 
Bolezni prebavil: Polipi fundičnih žlez (benigni) Pogostnost: pogosti
Package leaflet (acenocoumarol, phenprocoumon) 4 - Possible side effects 
Navodilo za uporabo (acenokumarol, fenprokumon) 4 - Možni neželeni učinki
A painful skin rash. 
Boleč izpuščaj na koži.
Methylphenidate - Priapism (EPITT no 18719) 
Metilfenidat - priapizem (št. EPITT 18719)
Proton pump inhibitors (PPIs): dexlansoprazole; esomeprazole; lansoprazole; omeprazole ; pantoprazole; rabeprazole - Gastric polyps (EPITT no 18725) 
Zaviralci protonske črpalke (PPI): dekslansoprazol, esomeprazol, lansoprazol, omeprazol, pantoprazol, rabeprazol - želodčni polipi (št. EPITT 18725)
Reproductive system and breast disorders Priapism, erection increased and prolonged erection Frequency: not known 
Motnje reprodukcije in dojk Priapizem, pogostejše erekcije in dolgotrajna erekcija Neznana pogostnost
Rare cases of calciphylaxis have been reported in patients taking vitamin K antagonists including <product name>, also in the absence of renal disease. 
Redki primeri pojava kalcifilaksije so bili opaženi pri bolnikih, ki so jemali antagoniste vitamina K, vključno z zdravilom <ime zdravila>, tudi če niso imeli bolezni ledvic.
Rare cases of calciphylaxis have been reported in patients taking vitamin K antagonists, also in the absence of renal disease. 
Redki primeri pojava kalcifilaksije so bili opaženi pri bolnikih, ki so jemali antagoniste vitamina K, tudi če niso imeli bolezni ledvic.
Summary of product characteristics (acenocoumarol, phenprocoumon) 
Povzetek glavnih značilnosti zdravila (acenokumarol, fenprokumon)
Bullous or exfoliative Exfoliative and bullous skin lesions, including bullous pemphigoid Frequency: not known 
Bulozne ali eksfoliativne Eksfoliativne in bulozne kožne lezije, vključno z buloznim pemfigoidom Neznana pogostnost
Prolonged and painful erections have been reported in association with methylphenidate products, mainly in association with a change in the methylphenidate treatment regimen. 
V povezavi z zdravili z metilfenidatom, v glavnem v povezavi s spremenjenim režimom zdravljenja z metilfenidatom, so poročali o dolgotrajnih in bolečih erekcijah.
Acenocoumarol; phenprocoumon; fluindione; phenindione - Calciphylaxis (EPITT no 18710) 
Acenokumarol, fenprokumon, fluindion, fenindionkalcifilaksija (št. EPITT 18710)
What is ginger? 
Kaj je ingver?
Moreover, these intended uses do not require medical supervision. 
Poleg tega predvidena uporaba ne zahteva zdravniškega nadzora.
EMA/HMPC/296580/2012 
EMA/HMPC/296580/2012 Odbor za zdravila rastlinskega izvora (HMPC)
Ginger is the common name for the whole or cut rhizome (underground stems) of the plant Zingiber officinale. 
Ingver je splošno ime za celo ali narezano koreniko (podzemni del stebla) rastline Zingiber officinale.
When serotonin attaches to these receptors it causes nausea and vomiting. 
Vezava serotonina na te receptorje povzroči slabost in bruhanje.
This summary is not intended to provide practical advice on how to use medicines containing ginger. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo ingver.
The exact way ginger acts on the stomach and gut is not fully known, but it is thought to work by blocking certain receptors for the hormone 5HT3, known as serotonin, which are involved in the contraction of the smooth muscles inside the stomach and gut. 
Natančen mehanizem delovanja ingverja na želodec in črevesje ni popolnoma znan, vendar menijo, da zavira nekatere receptorje hormona 5HT3, imenovanega serotonin, ki so vključeni v krčenje gladkih mišic v želodcu in črevesu.
This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU. 
To pomeni, da obstajajo podatki v literaturi z znanstvenimi dokazi o učinkovitosti in varnosti teh zdravil, če se uporabljajo, kot je navedeno, in ki v EU zajemajo obdobje vsaj 10 let.
In its assessment, the HMPC considered a number of clinical studies with ginger, looking at its effectiveness in treating different conditions. 
Pri svoji oceni je odbor HMPC upošteval številne klinične študije z ingverjem, ki so preučevale njegovo učinkovitost pri zdravljenju različnih stanj.
How does ginger work as a medicine? 
Kako ingver deluje kot zdravilo?
The plant is cultivated or gathered to obtain the rhizome for medicinal use. 
Rastlina se prideluje ali nabira za pridobivanje korenike za medicinsko uporabo.
Further information on the risks associated with ginger medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo ingver, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
It also concluded that, on the basis of its long-standing use, ginger can be used in adults to treat the symptoms of mild complaints affecting the stomach or gut (including bloating and flatulence), and in adults and children aged six and above to treat the symptoms of motion sickness. 
Prav tako je zaključil, da se lahko na podlagi njegove dolgoletne uporabe ingver pri odraslih uporablja za zdravljenje simptomov blagih težav z želodcem ali črevesom (vključno z napihnjenostjo in vetrovi) ter pri odraslih in otrocih, starih šest let ali več, za zdravljenje simptomov potovalne bolezni.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of ginger. 
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo ingverja.
The HMPC concluded that ginger can be used in adults to prevent nausea and vomiting in motion sickness. 
Odbor HMPC je zaključil, da se lahko ingver uporablja pri odraslih za preprečevaje slabosti in bruhanja pri potovalni bolezni.
How are ginger medicines approved in the EU? 
Kako so zdravila, ki vsebujejo ingver, odobrena v EU?
Other information about ginger medicines 
Druge informacije o zdravilih, ki vsebujejo ingver
Herbal medicines containing ginger are usually available in solid forms and are taken by mouth. 
Zdravila rastlinskega izvora, ki vsebujejo ingver, so navadno na voljo v trdnih oblikah, ki se jemljejo peroralno (zaužijejo skozi usta).
Detailed instructions on how to take ginger-containing medicines and who can use them can be found in the package leaflet that comes with the medicine. 
Podrobna navodila o tem, kako jemati zdravila z ingverjem in o tem, kdo jih lahko jemlje, so v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing ginger. 
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo ingver.
The results showed that ginger was more effective than placebo and as effective as other medicines in preventing motion sickness. 
Rezultati so pokazali, da je bil ingver pri preprečevanju potovalne bolezni učinkovitejši od placeba in enako učinkovit kot druga zdravila.
Information on the use and licensing of ginger medicines in EU Member States should be obtained from the relevant national authorities. 
Za informacije o uporabi in dovoljenjih za promet z zdravili, ki vsebujejo ingver, v državah članicah EU se obrnite na pristojni nacionalni organ.
Any applications for the licensing of medicines containing ginger have to be submitted to the national authorities responsible for medicinal products, which will assess the herbal medicine and take into account the scientific conclusions of the HMPC. 
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo ingver, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
What evidence supports the use of ginger medicines? 
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo ingver?
Common side effects (seen between 1 and 10 patients in 100) have been reported with ginger, mostly affecting the stomach and gut: stomach upset, eructation (belching), dyspepsia (heartburn) and nausea (feeling sick). 
Pri ingverju so poročali o pogostih neželenih učinkih (ki se pojavijo pri od 1 do 10 bolnikih od 100), ki prizadenejo predvsem želodec in črevesje: razdražen želodec, spahovanje, dispepsija (zgaga) in navzea (občutek slabosti).
What are the risks associated with ginger medicines? 
Kakšna tveganja so povezana z zdravili, ki vsebujejo ingver?
In particular, ginger has been compared with placebo (a dummy treatment) or other treatments in the prevention of nausea and vomiting in motion sickness. 
Ingver so primerjali predvsem s placebom (zdravilom brez zdravilne učinkovine) ali drugimi oblikami zdravljenja pri preprečevanju slabosti in bruhanja pri potovalni bolezni.
The HMPC conclusions on the use of ginger medicines for the treatment of symptoms of motion sickness and of mild complaints affecting the stomach or gut are based on their ‘traditional use' in these indications. 
Zaključki odbora HMPC glede uporabe zdravil za zdravljenje simptomov potovalne bolezni in blagih težav z želodcem ali črevesjem, ki vsebujejo ingver, temeljijo na njihovi „tradicionalni uporabi“ pri teh indikacijah.
The HMPC conclusions on the use of ginger medicines for the prevention of nausea and vomiting in motion sickness are based on their ‘well-established use' in this indication. 
Zaključki odbora HMPC o uporabi zdravil za preprečevanje slabosti in bruhanja pri potovalni bolezni, ki vsebujejo ingver, temeljijo na njihovi „dobro uveljavljeni uporabi“ za to indikacijo.
For practical information about using ginger medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravil z ingverjem naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
For more information about treatment with ginger, read the package leaflet that comes with the medicine or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravili, ki vsebujejo ingver, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
The herbal preparation is obtained by drying and powdering the rhizome. 
Pripravek rastlinskega izvora se pridobiva s sušenjem korenike in njeno predelavo v prašek.
Further information on the HMPC assessment of ginger, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o oceni zdravil, ki vsebujejo ingver, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“:
In addition, two Phase IIIb studies were conducted to support the clinical efficacy and safety of Trimbow. 
Izvedli so tudi dve študiji faze IIIb v podporo klinični učinkovitosti in varnosti zdravila Trimbow.
Trimbow contains a small amount of ethanol. 
Zdravilo Trimbow vsebuje majhno količino etanola.
Some medicines may increase the effects of Trimbow and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat). 
Nekatera zdravila lahko povečajo učinke zdravila Trimbow in zdravnik vas bo morda želel skrbno spremljati, če jemljete ta zdravila (vključno z nekaterimi zdravili za zdravljenje okužbe z virusom HIV: ritonavirjem, kobicistatom).
Using Trimbow together with: 
Uporaba zdravila Trimbow skupaj z:
injection, 40% of the dose was excreted in the urine within 24 hours. 
injekciji glikopironija se je 40 % odmerka izločilo v urinu v 24 urah.
Caution should also be exercised when treating patients with known or suspected prolongation of the QTc interval (QTc > 450 milliseconds for males, or > 470 milliseconds for females), either congenital or induced by medicinal products as these patients were excluded from clinical trials with Trimbow. 
Previdnost je potrebna tudi pri zdravljenju bolnikov z znanim podaljšanjem intervala QTc ali sumom nanj (QTc > 450 milisekund za moške ali > 470 milisekund za ženske), bodisi prirojenim ali povzročenim z zdravili, saj so bili ti bolniki izključeni iz kliničnih preskušanj z zdravilom Trimbow.
If you are using Trimbow or high doses of other inhaled corticosteroids over long periods and you come into a situation of stress (e.g. being taken to hospital after an accident, having a serious injury or before an operation) you may need more of this medicine. 
Če uporabljate zdravilo Trimbow ali velike odmerke inhaliranih kortikosteroidov in ste v stresni okoliščini (npr. če vas po nesreči odpeljejo v bolnišnico, če imate resno poškodbo ali pred operacijo) boste morda potrebovali več tega zdravila.
It is recommended that treatment with Trimbow should not be stopped abruptly. 
Priporoča se, da se zdravljenja z zdravilom Trimbow ne prekine nenadoma.
If anaesthesia with halogenated anaesthetics is planned, it should be ensured that Trimbow is not administered for at least 12 hours before the start of anaesthesia as there is a risk of cardiac arrhythmias. 
Če je načrtovana anestezija s halogeniranimi anestetiki, je treba zagotoviti, da se zdravilo Trimbow ne uporabi vsaj 12 ur pred začetkom anestezije, saj obstaja tveganje srčnih aritmij.
This includes medicines similar to Trimbow used for your lung disease. 
To vključuje zdravila, podobna zdravilu Trimbow, ki se uporabljajo za zdravljenje pljučnih bolezni.
What Trimbow is and what it is used for What you need to know before you use Trimbow How to use Trimbow 
Kaj je zdravilo Trimbow in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Trimbow Kako uporabljati zdravilo Trimbow
The aerosol particles of Trimbow are on average much smaller than the particles delivered in non-extrafine formulations. 
Aerosolni delci zdravila Trimbow so povprečno veliko manjši kot delci v formulacijah, ki niso v obliki izredno majhnih delcev.
If you see 'mist' coming from the top of the inhaler or the sides of your mouth, this means that Trimbow will not be getting into your lungs as it should. 
Če opazite, da z vrha inhalatorja ali ob robu ust uhaja »meglica«, to pomeni, da zdravilo Trimbow ne bo prišlo v vaša pljuča tako, kot bi moralo.
Trimbow does not contain a high-dose inhaled corticosteroid, but your doctor may wish to measure the cortisol levels in your blood from time to time. 
Zdravilo Trimbow ne vsebuje velikih odmerkov inhalacijskih kortikosteroidov, vendar bo morda zdravnik želel občasno izmeriti raven kortizola v krvi.
Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using Trimbow and to contact their doctor immediately should any of these signs or symptoms develop. 
Bolnike je treba obvestiti o znakih in simptomih akutnega glavkoma z zaprtim zakotjem in jim naročiti, naj prenehajo uporabljati zdravilo Trimbow in se takoj posvetujejo z zdravnikom, če se pojavijo ti znaki ali simptomi.
There are no relevant data on the use of Trimbow in patients with severe hepatic impairment and the medicinal product should be used with caution in these patients (see section 4.4 and section 5.2). 
Relevantnih podatkov o uporabi zdravila Trimbow pri bolnikih s hudo okvaro jeter ni, zato je treba zdravilo pri teh bolnikih uporabljati previdno (glejte poglavje 4.4 in poglavje 5.2).
Tell your doctor if you have used more Trimbow than you should and if you experience any of these symptoms. 
Zdravniku povejte, če ste uporabili več zdravila Trimbow, kot bi smeli, in imate katerega od teh simptomov.
You should only use Trimbow during pregnancy if you are advised to do so by your doctor. 
Zdravilo Trimbow uporabljajte med nosečnostjo le, če vam tako svetuje zdravnik.